Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 10,356 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Congenital, Hereditary, and Neonatal Diseases and Abnormalities Clear all

Conditions: Achondroplasia
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypospadias
Interventions: Randomization to not receive prophylactic antibiotics after surgery., Randomization to receive prophylactic antibiotics after surgery; Other
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 3 Months to 6 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Neurofibromatosis Type 1
Interventions: Whole-body Magnetic Resonance Imaging; Other
Lead sponsor: Nicole Baca; Other
Eligibility: 5 Years to 17 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prematurity, BPD - Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Newborn
Interventions: Volume Targeted Ventilation (VTV) using the Philips Respironics NM3 monitor, Tidal Volume Measurement using the Philips Respironics NM3 monitor; Device
Lead sponsor: Baystate Medical Center; Other
Eligibility: 5 Minutes to 60 Minutes
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
Interventions: Bardoxolone methyl capsules; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more

Conditions: Huntington's Disease
Interventions: PF-02545920, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more

Conditions: Thyroid Eye Disease
Interventions: Satralizumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: San Diego, California • Danbury, Connecticut • Chicago, Illinois + 3 more

Conditions: End Stage Renal Failure, Hemodialysis Access Failure, Arterio-venous Fistula
Interventions: One stage approach; Procedure
Lead sponsor: Tze-Woei Tan; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Colorectal Cancer, Hereditary Non-polyposis Colon Cancer, Precancerous Condition
Interventions: study of socioeconomic and demographic variables, evaluation of cancer risk factors, study of high risk factors; Other · Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: Up to 100 Years
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Atopic Dermatitis
Interventions: Crisaborole 2%, Vehicle; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 3 Months and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 25
States / cities: Fountain Valley, California • Fremont, California • Colorado Springs, Colorado + 20 more

Conditions: Down Syndrome
Interventions: [18F]MK-6240; Biological
Lead sponsor: LuMind IDSC Foundation; Other
Eligibility: 35 Years to 55 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked in Syndrome, Muscular Dystrophies
Interventions: BrainGate Neural Interface System; Device
Lead sponsor: Leigh R. Hochberg, MD, PhD.; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Stanford, California • Boston, Massachusetts

Conditions: Pregnancy Related, COVID, Intestinal Atresia, Limb Anomaly
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Epilepsy
Interventions: retigabine/ezogabine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 29 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Wellington, Florida • Memphis, Tennessee + 1 more

Conditions: Long QT Syndrome
Interventions: Placebo, Ranolazine; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 21 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Huntington's Disease
Interventions: FuRST 2.0; Behavioral
Lead sponsor: CHDI Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 3
States / cities: Englewood, Colorado • Wichita, Kansas • New York, New York

Conditions: Congenital Heart Disease
Interventions: Pulmonary Valve Replacement Surgery; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Months to 16 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Sickle Cell Disease
Interventions: MRI, Transthoracic Echocardiography, tonometry, EKG; Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cardiomyopathy, Dilated, Cardiomyopathy, Hypertrophic, Insulin Resistance
Interventions: Oral glucose tolerance test; Diagnostic Test
Lead sponsor: Le Bonheur Children's Hospital; Other
Eligibility: 13 Years to 18 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Hypoplastic Left Heart Syndrome, Atrioventricular Canal
Interventions: MPC; rexlemestrocel-L; Biological
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 5 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adult Cystic Nephroma, Anaplastic Kidney Wilms Tumor, Angiolipoma, Cellular Congenital Mesoblastic Nephroma, Classic Congenital Mesoblastic Nephroma, Clear Cell Sarcoma of the Kidney, Congenital Mesoblastic Nephroma, Cystic Partially Differentiated Kidney Nephroblastoma, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Extrarenal Rhabdoid Tumor, Kidney Medullary Carcinoma, Kidney Neoplasm, Kidney Oncocytoma, Kidney Wilms Tumor, Metanephric Adenofibroma, Metanephric Adenoma, Metanephric Stromal Tumor, Metanephric Tumor, Mixed Congenital Mesoblastic Nephroma, Ossifying Renal Tumor of Infancy, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Rhabdoid Tumor of the Kidney, Wilms Tumor
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 29 Years
Enrollment: 8,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2026
U.S. locations: 214
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more

Conditions: Gout, Low Medication Adherence, Health Related Quality of Life
Interventions: Gout Storytelling Video Intervention; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 19 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Birmingham, Alabama • St Louis, Missouri • Philadelphia, Pennsylvania

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: ravuconazole; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rett Syndrome
Interventions: TSHA-102; Genetic
Lead sponsor: Taysha Gene Therapies, Inc.; Industry
Eligibility: 5 Years to 8 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 3
States / cities: Chicago, Illinois • Saint Paul, Minnesota • St Louis, Missouri

Search by objective public record fields.

Achondroplasia Natural History Multicenter Clinical Study

Antibiotic Use in Distal Hypospadias Repair

Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence

Feasibility and Impact of Volume Targeted Ventilation in the Delivery Room

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX

Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

Outcomes for One-stage and Two-stage Brachial Basilic Arteriovenous Fistulas

Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer

A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

LIFE-DSR-Biomarker Sub-study of Biomarkers in Down Syndrome Related Alzheimer's Disease (DS-AD)

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia

In-Utero Vascular Accidents in Neonates From COVID-19 Infected Mothers

Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients

FuRST 2.0 Cognitive Pre-Testing

Autus Valve Continued Access Study (CAS)

Cardiovascular Complications of Sickle Cell Disease

Association of Insulin Resistance and FGF21 on Cardiac Function in Pediatric Dilated Cardiomyopathy

Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle

Study of Kidney Tumors in Younger Patients

SToRytelling to Improve DiseasE Outcomes in GOut: The STRIDE-GO2 Study

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)